SCHEMBL2763448

SCHEMBL2763448

Oc1cccc2c1Sc1ccccc1N2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 11/20 0.59
MAPT P10636 8/20 0.59
GAA P10253 8/20 0.59
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
SNCA P37840 3/20 0.59
TDP1 Q9NUW8 3/20 0.59
BCHE P06276 2/20 0.59
ACHE P22303 2/20 0.59
ALOX15 P16050 2/20 0.59
CYP1A2 P05177 1/20 0.59
POLB P06746 1/20 0.59
CYP3A4 P08684 1/20 0.59
ADORA3 P0DMS8 1/20 0.59
ALOX12 P18054 1/20 0.59
MAOA P21397 1/20 0.59
CNR1 P21554 1/20 0.59
PTGS1 P23219 1/20 0.59
SLC6A2 P23975 1/20 0.59
HTR2C P28335 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenothiazine SCHEMBL6025548 0.84 NOX1 (0.77) NOX1MAPTGAAMEN1KMT2A
SCHEMBL17073945 0.80 NOX1 (0.64) NOX1MAPTGAAMEN1KMT2A
SCHEMBL9813115 0.79 NOX1 (0.52) NOX1MAPTGAAMEN1KMT2A
SCHEMBL28063927 0.77 NOX1 (0.59) NOX1MAPTGAAMEN1KMT2A
SCHEMBL7557742 0.77 NOX1 (0.59) NOX1MAPTGAAMEN1KMT2A
SCHEMBL7235228 0.77 NOX1 (0.59) NOX1MAPTGAAMEN1KMT2A
SCHEMBL7069691 0.77 NOX1 (0.59) NOX1MAPTGAAMEN1KMT2A
SCHEMBL344333 0.77 NOX1 (0.59) NOX1MAPTGAAMEN1KMT2A
SCHEMBL28438576 0.77 NOX1 (0.53) NOX1MAPTGAAMEN1KMT2A
Phenothiazine SCHEMBL9114 0.76 NOX1 (1.00) NOX1MAPTGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1485377-B9 PYRANONES USEFUL AS ATM INHIBITORS KUDOS PHARM LTD (GB) 2010-10-06 EP disclosed
EP-1485377-B9 PYRANONES USEFUL AS ATM INHIBITORS KUDOS PHARM LTD (GB) 2010-10-06 EP disclosed
CN-1867566-B Aminopyranones and their use as ATM inhibitors KUDOS PHARM LTD 2010-06-16 CN disclosed
EP-2174939-A1 Pyranones useful as ATM inhibitors Kudos Pharmaceuticals Limited (GB) 2010-04-14 EP disclosed
EP-2174939-A1 Pyranones useful as ATM inhibitors Kudos Pharmaceuticals Limited (GB) 2010-04-14 EP disclosed
EP-1654257-B1 AMINOPYRONES AND THEIR USE AS ATM INHIBITORS KUDOS PHARM LTD (GB) 2010-03-17 EP disclosed
EP-1654257-B1 AMINOPYRONES AND THEIR USE AS ATM INHIBITORS KUDOS PHARM LTD (GB) 2010-03-17 EP disclosed
EP-1485377-B1 PYRANONES USEFUL AS ATM INHIBITORS KUDOS PHARM LTD (GB) 2009-12-09 EP disclosed
EP-1485377-B1 PYRANONES USEFUL AS ATM INHIBITORS KUDOS PHARM LTD (GB) 2009-12-09 EP disclosed
US-20090043091-A1 Induce immunology response; anticancer agents; 6-(6-Morpholin-4-yl-4-oxo-4H-pyran-2-yl)-thianthrene-2-carboxylate sodium salt; 6-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-thianthrene-2-carboxylic acid methyl ester KUDOS PHARMACEUTICALS LIMITED (GB) 2009-02-12 US disclosed
CN-1867566-A Aminopyranones and their use as ATM inhibitors KUDOS PHARM LTD (GB) 2006-11-22 CN disclosed
WO-2006069276-A2 TRICYCLIC ō-OPIOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-29 WO disclosed
US-7049313-B2 ATM inhibitors KUDOS PHARMACEUTICALS LTD. (GB) 2006-05-23 US disclosed
EP-1654257-A1 AMINOPYRONES AND THEIR USE AS ATM INHIBITORS Kudos Pharmaceuticals Limited (GB) 2006-05-10 EP disclosed
CN-1639154-A Pyranones useful as ATM inhibitors KUDOS PHARM LTD (GB) 2005-07-13 CN disclosed
US-20050054657-A1 ATM inhibitors KUDOS PHARMACEUTICALS LIMITED (GB) 2005-03-10 US disclosed
WO-2005016919-A1 AMINOPYRONES AND THEIR USE AS ATM INHIBITORS KUDOS PHARMACEUTICALS LIMITED (GB) 2005-02-24 WO disclosed
EP-1485377-A1 PYRANONES USEFUL AS ATM INHIBITORS Kudos Pharmaceuticals Limited (GB) 2004-12-15 EP disclosed
US-20040002492-A1 Induce immunology response; anticancer agents KUDOS PHARMACEUTICALS LTD (GB) 2004-01-01 US disclosed
WO-2003070726-A1 PYRANONES USEFUL AS ATM INHIBITORS KUDOS PHARMACEUTICALS LTD (GB) 2003-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002492-A1 Induce immunology response; anticancer agents MYD88, IFNG, HCCS NOX1 124/4885MAPT 4832/4885GAA 4828/4885
US-20090043091-A1 Induce immunology response; anticancer agents; 6-(6-Morpholin-4-yl-4-oxo-4H-pyran-2-yl)-thianthrene-2-carboxylate sodium salt; 6-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-thianthrene-2-carboxylic acid methyl ester MYD88, MCL1, TLR1 NOX1 135/4885MAPT 4311/4885GAA 4864/4885
US-20050054657-A1 ATM inhibitors ATM, ATR, CHEK2 NOX1 576/4885MAPT 1236/4885GAA 3109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.